Showing results (11-20 of 3,147) with videos related to

Sort By:
Pageof 315
Neuro-Oncology|September 12, 2001
Preliminary results of conformal radiation therapy for medulloblastomaT E Merchant, L Happersett, J L Finlay, et al.
Neuro-Oncology|September 12, 2001
Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasoneR L Dean, D F Emerich, B P Hasler, et al.
Neuro-Oncology|September 12, 2001
Brain tumors in children with neurofibromatosis: additional neuropsychological morbidity?A E De Winter, B D Moore, J M Slopis, et al.
Neuro-Oncology|September 12, 2001
Response and progression in recurrent malignant gliomaK R Hess, E T Wong, K A Jaeckle, et al.
Neuro-Oncology|September 14, 2001
The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment GroupB P O'Neill, C H Wang, J R O'Fallon, et al.
Neuro-Oncology|June 21, 2003
The prognostic value of neurologic function in astrocytic spinal cord gliomaHoon K Lee, Eric L Chang, Gregory N Fuller, et al.
Neuro-Oncology|June 21, 2003
The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experienceIan F Pollack, James M Boyett, Allan J Yates, et al.
Neuro-Oncology|April 4, 2003
Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progressionChristina A Meyers, Kenneth R Hess
Neuro-Oncology|April 4, 2003
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant gliomaMichael D Prados, S Clifford Schold, Howard A Fine, et al.
Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.
Pageof 315